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Abstract 
Background: Children born with a small or absent ear undergo surgical reconstruction to create a suitable replace-
ment using rib cartilage. To overcome the donor site morbidity and long-term pain of harvesting rib cartilage, syn-
thetic materials can be a useful alternative. Medpor, is the currently used synthetic polyethylene material to replace 
missing facial cartilage but unfortunately it has high levels of surgical complications including infection and extrusion, 
making it an unsuitable replacement. New materials for facial cartilage reconstruction are required to improve the 
outcomes of surgical reconstruction. This study has developed a new nanomaterial with argon surface modification 
for auricular cartilage replacement to overcome the complications with Medpor.
Results: Polyurethanes nanocomposites scaffolds (PU) were modified with argon plasma surface modification (Ar) 
and compared to Medpor in vitro and in vivo. Ar scaffolds allowed for greater protein adsorption than Medpor and 
PU after 48 h (p < 0.05). Cell viability and DNA assays demonstrated over 14-days greater human dermal fibroblast 
adhesion and cell growth on Ar than PU and Medpor nanocomposites scaffolds (p < 0.05). Gene expression using 
RT-qPCR of collagen-I, fibronectin, elastin, and laminin was upregulated on Ar scaffolds compared to Medpor and PU 
after 14-days (p < 0.05). Medpor, unmodified polyurethane and plasma modified polyurethane scaffolds were subcu-
taneously implanted in the dorsum of mice for 12 weeks to assess tissue integration and angiogenesis. Subcutane-
ous implantation of Ar scaffolds in mice dorsum, demonstrated significantly greater tissue integration by H&E and 
Massons trichrome staining, as well as angiogenesis by CD31 vessel immunohistochemistry staining over 12-weeks 
(p < 0.05).
Conclusions: Argon modified polyurethane nanocomposite scaffolds support cell attachment and growth, tissue 
integration and angiogenesis and are a promising alternative for facial cartilage replacement. This study demonstrates 
polyurethane nanocomposite scaffolds with argon surface modification are a promising biomaterial for cartilage tis-
sue engineering applications.
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Introduction
Surgical reconstruction of ear cartilage is required after 
trauma, infection, burns and congenital diseases [1–5]. 
Microtia, translated from the Greek, means little ear 
and is the medical word to describe a small or absent 
ear in newborn babies. The surgical reconstruction of 
the ear was first described by Tanzer et  al. who used a 
six-stage procedure [6]. Since then Brent and Nagata 
modified the technique to a two-stage procedure, which 
has now become the most commonly used method of 
autologous ear reconstruction [7, 8]. In this procedure, 
cartilage is harvested from the ribs and carved into an 
auricular shape to place beneath the subcutaneous tis-
sue. At approximately 6-months post the first procedure, 
the patient undergoes a second procedure to elevate 
the framework from the side of the head by placing 
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further rib cartilage under the original carved structure. 
The main advantage of this technique is that rib car-
tilage is from the patient and thus is biocompatible but 
can be limited due to the amount of available rib carti-
lage. Despite being the gold standard technique, there 
are drawbacks to this autologous technique. Harvesting 
of rib cartilage has many surgical risks including pneu-
mothorax, atelectasis, chest-wall deformities and it may 
cause scar and post-operative pain [3, 9]. With time the 
cartilage can also resorb and warp in shape, creating 
unreliable end results. Furthermore, the good clinical 
outcomes originally described by Brent and Tanzer are 
not always achieved due to the technical challenges of 
performing the surgery [10]. Due to autologous rib car-
tilage providing potential donor site morbidity and the 
technical challenge of the surgery, synthetic materials can 
also be used to reconstruct the ear cartilage [11]. Several 
prefabricated ‘off the shelf ’ framework materials have 
been developed for ear reconstruction. The most com-
monly used material is Medpor, a high-density polyeth-
ylene (HDPE, Medpor, Pores Surgical Inc.). Medpor was 
developed in the 1970s and first reported for use in 1983 
for reconstructive purposes [12–14]. However, reports 
of infection and extrusion with Medpor have prevented 
its widespread use [14]. This has prompted the need to 
develop alternative materials to improve the outcomes of 
synthetic auricular reconstruction.
Nanomaterials provide an alternative source of materi-
als for cartilage replacement that have dimensions that 
mimic the native extracellular environment allowing 
the surrounding cells to adhere to the material and lay 
down their own extracellular matrix (ECM). However, 
finding the optimal nanomaterial to replace cartilage 
has yet to be identified. Polyurethanes pose a frequently 
used polymer choice for several biomedical applications 
[15]. Polyurethanes have a broad range of mechanical 
properties from rigid materials to soft elastomers [15]. 
Due to encouraging biocompatibility and hemocompat-
ibility already reported, our group have been developing 
a nanocomposite polyurethane to mimic human auricu-
lar cartilage. Our nanocomposite material consists of a 
polyhedral oligomeric silsesquioxanes (POSS) modified 
polyurethane.
We have previously demonstrated that nanocomposite 
polyurethanes can be useful to replace auricular carti-
lage [16]. Polyurethanes with a pore size of 150–250 μm 
allowed for tissue ingrowth over 12  weeks in a rodent 
model [16]. However, one of the main problems with 
polyurethane biomaterials for regenerative purposes 
is that their surface is hydrophobic. Hydrophobicity or 
wettability of the material has a direct effect on protein 
absorption, its conformation, and thus eventually on cell 
attachment and consequently levels of tissue integration 
and angiogenesis [17]. Surface modification of biomateri-
als enables their surface to become more favourable for 
protein adsorption and consequently cell adhesion [18]. 
If cells adhere to a biomaterial surface then the implant is 
anchored to the surrounding tissue, preventing extrusion 
and infection of the biomaterial.
The surface of a biomaterial can be functionalised 
using two main techniques including physical and chemi-
cal modification to improve cell adhesion [19]. Physi-
cal modification can include modification of the surface 
topography to include pits or troughs to improve cell 
adhesion [20, 21]. However, this does not always provide 
the required molecules to induce appropriate signal-
ling pathways for cell adhesion and differentiation [19]. 
Physical modification also includes the coating of bioma-
terial surfaces with ECM cell adhesive proteins includ-
ing fibronectin, vitronectin, collagen or laminin [19]. 
The coating elicits cell directed new tissue formation by 
mediating biomolecular recognition. However, the cor-
rect protein, dose, orientation and half-life of the protein 
to achieve desired tissue responses are still under inves-
tigation [19]. Furthermore, the protein is susceptible to 
proteolytic degradation in the in vivo environment, limit-
ing the potential clinical application of this approach [19]. 
Alternatively chemical modification includes the immo-
bilization of various bioactive molecules on the surface. 
Covalent immobilization of RGD peptides or small pro-
tein fragments has shown to improve cell adhesion on 
different biomaterial surfaces [22, 23]. This approach has 
many advantages but is also associated with certain limi-
tations [19]. Scaffold morphology can cause difficulties 
for chemical immobilisation, preventing optimal number 
and orientation of reactive sites for the molecules [19]. To 
overcome the limitations of these approaches would be to 
find a technique, which can modify the surface’s topogra-
phy and induce a chemical functionalization.
Plasma surface modification (PSM) is one established 
technique, which creates a hydrophilic surface and can 
improve cell adhesion. PSM modifies the surface topog-
raphy and immobilises chemical functional groups onto 
the surface [24–26]. Plasma is defined as a gas in the 
ionised state and was introduced by Langmuir in 1928 
[27]. Applying a potential through a gas generates plasma 
modification. Radiofrequency plasma is the most widely 
used biomaterial surface treatment and involves passing 
an electric current through a gas at low or high pressure. 
Several studies have shown the beneficial effects of PSM 
on cell adhesion, proliferation and differentiation due to 
the surface topographical and chemical immobilization 
it creates [16, 25–28]. Hence, this study modified nano-
composite polyurethane implants with PSM to make 
it a suitable replacement for auricular reconstruction. 
We have shown previously that argon PSM is a superior 
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surface modification technique compared to nitrogen 
and oxygen plasma treatment in improving cell adhesion, 
extracellular growth formation and tissue integration and 
vascularisation in vivo [28]. The surface’s physiochemical 
properties of the argon modified polyurethanes scaffold’s 
has been fully characterised demonstrating a hydrophilic 
and etched surface compared to unmodified polyure-
thane scaffolds [28].
To examine if PSM can be used to develop a suitable 
nanocomposites biomaterial for cartilage replacement, 
this study aimed to compare the modified polyurethane 
against Medpor. This study has conducted an in depth 
in  vitro and in  vivo investigation of PU modified with 
argon plasma (Ar), unmodified polyurethane (PU) and 
Medpor to evaluate differences in tissue integration, 
angiogenesis and immune response. This study provides 
evidence that nanocomposites polyurethane with argon 
surface modification holds promise provides an alterna-
tive scaffold for cartilage tissue engineering.
Materials and methods
Polyurethane manufacture and plasma surface 
modification (PSM)
In this paper, all in  vitro and in  vivo experiments were 
conducted on the three scaffolds; unmodified polyure-
thane (PU), argon modified polyurethane (Ar), and Med-
por (0.85  mm thickness sheet, Porex Surgical, Newnan, 
GA, USA). PU scaffolds were synthesised and fabricated 
as described previously [16, 28–30]. In brief, polycarbon-
ate polyol (2000 Mwt) and transcyclohexanechloroy-
drinisobutyl-silses-106 quioxane (Hybrid plastics Inc.) 
was mixed with POSS cages. To form the pre-polymer 
4,4-methylenebis (phenyl 109 isocyanate) MDI was added 
to the solution. Then ethylenediamine and diethylamine 
was added slowly in DMAC to the mixture. The scaf-
folds were then fabricated using a previously described 
porogen leaching/solvent casting technique [16, 28–30]. 
In summary, the POSS-modified polycarbonate urea-
urethane polymer solution was mixed with sodium chlo-
ride porogen (NaCl with pore size 150–250  μm) in a 
ratio of 1.1. The slurry was then mixed and degassed in 
a Thinky AER 250 mixer (Intertronics, Kidlington, UK). 
The mixture was then coated onto titanium moulds and 
heated for 4 h at 65 °C degrees. Following immersion in 
deionised water to dissolve the NaCl and DMAC for 24 h, 
the procedure was repeated until the final thickness of 
0.85 mm was reached. Following the final layer, the scaf-
folds were further washed in deionised water for a further 
7 days to ensure all the NaCl and DMAC was removed. 
Subsequently the PU scaffolds were modified with argon 
modification and referred to as Ar scaffolds. Unmodified 
PU scaffolds and referred to as PU. Argon modification of 
PU scaffolds was performed by exposing the scaffolds to 
5  min using a radiofrequency plasma generator operat-
ing at 40 kHz with gas flow of 0.4 mbar at 100 W. Subse-
quently, for in vitro and in vivo experiments, 16 mm disks 
were cut from the polymer sheets.
Assessment of HDF response in vitro
Cell culture and cell seeding
Human Dermal Fibroblast (HDFs) (European Collec-
tion of Cell Culture (ECACC) were maintained in Dul-
becco’s Modified Eagle’s medium (DMEM) with 10% 
Foetal Bovine Serum (FBS) and 1% antibiotic solutions 
(Sigma, UK). For in  vitro experiments, 16  mm scaffolds 
were placed into the 24-well plates, for 24 h in complete 
medium before cell seeding. Each scaffold was seeded 
with 1 × 104 cells/cm2 unless stated. Every three days the 
medium was changed.
Assessment of cell morphology
The cell morphology of the HDFs was assessed after 24 h 
on PU, Ar and Medpor using F-actin staining as previ-
ously described [16]. In summary, 15,000 cells were 
seeded onto the scaffolds for assessment. After 24 h, the 
medium was removed from the scaffolds and washed 
with PBS several times. The cells were then fixed with 4% 
(w/v) paraformaldehyde in PBS at 37  °C for 10–15 min. 
After washing with 0.1% Tween-20 thrice and incubation 
with 0.1% TritonX-100 for 5 min to improve permeability 
the cells were stained with Rhodamine-conjugated phal-
loidin (ThermoFisher Scientific, UK) in the ratio 1:40. 
Following further washing, the cells were stained with 
DAPI (4′,6-diamidino-2-phenylindole, 1:500) to stain the 
nuclei. The scaffolds were then visualised to assess cell 
circularity and cell area (cell surface stained with actin) 
using ImageJ Software (n = 30 cells).
Assessment of cell adhesion and growth
The adhesion and growth of the HDFs onto the scaffolds 
was analysed using Fluorescence Hoechst DNA Quantifi-
cation Kit (Sigma, UK) as described previously [16] after 
1, 2, 4, 7, 10 and 14  days. In brief 200 μL of deionized 
deniosed water was added to the scaffolds at each time 
point followed by three freeze–thaw cycles to extract 
DNA from the scaffolds. A DNA standard curve was for-
mulated by staining the DNA with bisBenzimide H 33258 
solution, using the DNA standards provided. The fluores-
cence was measured with excitation and emission wave-
lengths of 360 nm and 460 nm using a Fluoroskan Ascent 
FL, (Thermo Labsystems, UK).
Gene expression
The gene expression of adhesion, extracellular matrix 
and angiogenesis was evaluated using RT-qPCR as pre-
viously described [30]. Firstly, RNA was extracted using 
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Tri-Reagent (Life Technologies, UK). Then, Moloney 
murine leukemia virus reverse transcriptase was used 
to retro-transcribe the RNA (Promega, Madison, WI). 
Lastly, Real Time quantitative Polymerase Chain Reaction 
(RT-qPCR) was completed using with ABI Prism 7500 
sequence detection system (Applied Biosystems) with 
QuantiTect SYBR Green PCR kit (Qiagen, Hilden, Ger-
many). The housekeeping gene Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) was used to normalise 
the data using the  2−ΔΔCt method. Primer sequences and 
annealing temperatures for each set of primers was used 
as previously described [30].
Assessment of collagen production by HDFs
Collagen Type-I after 14  days was also examined using 
immunocytochemistry as previously described [31]. 
At 14  days, the medium was removed and the scaffolds 
were washed and fixed in 4% paraformaldehyde. Follow-
ing incubation overnight, the scaffolds were washed with 
PBS. Subsequently, the scaffolds were permeabilized with 
(0.5% Triton x-100) and blocked with 0.5% Bovine Serum 
Albumin (BSA). Following incubation with primary 
antibody overnight at 4  °C 1:200 (abcam, uk ab34710), 
the scaffolds were washed thoroughly. After incubation 
with secondary antibody for 2 h (alexa fluor 488, 1:500) 
at room temperature, the cell nuclei were stained with 
Hoechst 33258 (2.5 μg/ml final concentration. Total col-
lagen and hydroxyproline secretion was also examined 
after 7 and 14 days by the HDFs on the three scaffolds as 
previously described [32]. In brief, the extracellular total 
collagen production by cells was analysed using the Pic-
roSirius Red (PSR) method as originally described (n = 6) 
[32]. Medium from the scaffolds was taken after to meas-
ure hydroxyproline content using a QuickZyme hydroxy-
proline assay kit (Biosciences) (n = 6) as described by 
previously [32].
Assessment of VEGF secretion by ELIZA using HDFs
The secretion of VEGF was examined from the HDFs 
after 4, 7, 10 and 14 days using ELISA analysis as previ-
ously described (ELISA, quantikine, R&D system, Abing-
don, UK) [32]. In brief, cell culture supernatants at the 
required time points was centrifuged at 200g for 10 min 
and then stored at − 20  °C. The supernatants were then 
placed in ELISA 96-well plates coated with monoclonal 
antibody specific for VEGF. Following incubation for 2 h 
at room temperature, the enzyme linked anti-VEGF pol-
yclonal antibody was added and incubated for a further 
20 min. The colour was stopped using stop solution and 
the colour intensity measured with a colorimetric plate 
reader (Anthos 2020 microplate reader, Biochrome Ltd, 
UK) set at 450 nm and 540 nm wavelength.
Assessment of immune response in vitro
Macrophage responses to the PU scaffolds were investi-
gated by transformed U937 macrophage proliferation, 
cell morphology, and cytokines release assessments as 
previously described [32].
Macrophage cell culture
Macrophage cell culture was performed as described 
in Nayyer et  al. [32]. In brief, the human promonocytic 
cell line U937, isolated from a histiocytic lymphoma 
(ECACC, UK, Number 85011440), was cultured in 
RPMI-1640 supplemented with 10% Foetal Bovine Serum 
(FBS), 5% l-glutamine (2 mM) and 1% antibiotic (50 μg/
ml streptomycin, 50 U/ml penicillin) solutions (all from 
Sigma, UK) and incubated at 37  °C under a humidified 
atmosphere of 5% CO2. The nonadherent undifferenti-
ated U937 was washed (× 3) every 3 to 4 days in Hank’s 
balance solution. Each 16 mm polymer disc in a 24 well 
plate was seeded with U937 cells at a density of 1 × 105 
cells/cm2 in 1  ml of cell culture medium supplemented 
with 0.5  nM phorbol-12- myristate 13-acetate (PMA) 
(Sigma, UK). Under these conditions, U937 monocytes 
will adhere to surfaces and differentiate into macrophage-
like cells. After 24 h the wells were aspirated to remove 
any unattached and non-differentiated monocytes, and 
replaced with fresh medium. Lipopolysaccharide (LPS), a 
Gram-negative bacterium, (Sigma, UK) stimulated trans-
formed macrophages on the polymer surfaces at a con-
centration of 1 μg/ml as a positive control.
Macrophage adhesion and growth
The adhesion and growth of the macrophages was 
assessed after 1, 4, 7 and 10 days on the materials using 
DNA assay as described above.
Macrophage cytokine release
Cytokines release including TNF-α, IL-10 and IL-β quan-
tification using a sandwich ELISA assay (Quantikine, 
R&D System, Abingdon, UK) and performed in response 
to the different scaffolds after 1, 4, 7, and 10 days as pre-
viously described [32].
In vivo analysis
Subcutaneous implantation of PU, Ar, and Medpor 
scaffolds was examined in a subcutaneous mouse 
implantation model for 6 and 12  weeks as described 
previously [16]. Of each scaffolds, two 4  mm discs 
were subcutaneously implanted in the dorsum of one 
4-month-old BALB/c mice (Charles River Laborato-
ries, UK) (n = 6). The disc was implanted via a small 
incision and closed with interrupted 5,0 monocryl. All 
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experiments were approved by the local governmen-
tal animal care committee and performed according 
to animal welfare UK legislation. At 6 and 12  weeks, 
using  CO2 asphyxiation the animal were scarified and 
the scaffolds excised in fixed in 4% paraformaldehyde. 
The scaffolds were excised with approximately 0.5  cm 
surrounding circular dermis. Fixed scaffolds were then 
paraffin embedded and cut into 3 μm sections for his-
tological analysis. H&E staining, Masson Trichrome 
staining was conducted according to standard proce-
dures to assess tissue integration and CD31 immuno-
histochemistry staining for endothelial cells detection 
as per a previous study [16].
Statistical analysis
The comparisons between the three scaffolds were ana-
lysed statistically using one-way analysis of variance 
(ANOVA) with Tukey HSD post hoc analysis (Prism6 
Software). In addition, the average and standard devia-
tion (SD) was calculated. Significance was described as 




As cells adhere via proteins to implant surface, the pro-
tein adsorption on the three surfaces was investigated. 
BCA assay showed the total protein adsorption onto 
the scaffolds was significantly the highest on Ar scaf-
folds after 24  h compared to Medpor and PU (Fig.  1a) 
(p < 0.05). PU showed similar BCA protein adsorption 
compared to Medpor over 24 h. Monoclonal antibodies 
were used to determine if fibronectin and vitronectin was 
adsorbed in the correct conformation on the different 
material surfaces (Fig. 1b, c). Vitronectin and fibronectin 
showed different levels of conformation on the scaffolds. 
Vitronectin was greatest on Ar surfaces and the lowest on 
Medpor scaffolds. The fibronectin adsorption was also 
significantly greatest on the Ar scaffolds compared to 
Medpor and POS-PCU scaffolds (p < 0.05).
Fig. 1 Protein adsorption studies on the polyurethane (PU), argon (Ar) and Medpor scaffolds. a Total protein adsorption on the Ar, Medpor, and 
PU scaffolds. Ar showed significantly greater protein adsorption compared to untreated PU and Medpor scaffolds (*p < 0.05). b Fibronectin and c 
vitronectin adsorption on the Ar, Medpor, and PU scaffolds. Ar scaffolds showed greater fibronectin adsorption than Medpor and PU scaffolds. Ar 
showed significantly higher vitronectin adsorption than Medpor and PU scaffolds. PU; Unmodified Polyurethane
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HDF in vitro assessment
HDF adhesion and growth
The morphology of the HDFs found showed a variety 
of morphologies on all surfaces. The HDF adopted a 
stretched morphology on Ar, Medpor, and PU scaffolds 
and were able to spread on the surfaces (Fig.  2a). The 
adhesion of the HDF was varied among the three sur-
faces after 24  h. DNA assay showed HDF adhesion was 
significantly higher on Ar than Medpor and PU scaffolds 
(p < 0.05) (Fig. 2b). Adhesion related genes including pax-
illin, talin, and vinculin were observed to be upregulated 
on the Ar scaffolds compared to the Medpor and PU scaf-
folds (p < 0.01) after 24 h (Fig. 2c). HDF cell growth was 
greatest over 14 days on Ar scaffolds compared to Med-
por and PU scaffolds using DNA assay (p < 0.05) (Fig. 2d). 
HDF on PU scaffolds showed significantly higher levels of 
DNA content from day 7 compared to HDFs on Medpor 
scaffolds (p < 0.05).
HDF angiogenesis
The secretion of VEGF protein by from the HDFs at 7 and 
14  days, was the greatest on the Ar scaffolds compared 
to Medpor and PU (Fig. 3a). Medpor showed the lowest 
secretion of angiogenic protein VEGF from 4 to 14 days 
(p < 0.05). The mRNA expression of VEGF was also exam-
ined after 14 days to assess angiogenesis. The HDFs on Ar 
scaffolds showed the greatest mRNA expression of VEGF 
(p < 0.05) (Fig.  3b). The HDFs on PU showed a greater 
upregulation of mRNA expression of VEGF compared to 
HDF on Medpor (p < 0.05).
HDF extracellular matrix formation
The expression of genes associated with formation of 
the extracellular matrix was examined including colla-
gen I (col-I), collagen (col-III), fibronectin (Fn), elastin 
(elastin), and laminin (Lm) (Fig.  4a). The HDFs on Ar 
scaffolds showed increased mRNA expression at 7 and 
Fig. 2 Human dermal fibroblast (HDF) adhesion in vitro studies on polyurethane (PU), argon (Ar) and Medpor scaffolds. a HDF morphology after 
24 h using F-actin staining on the PU and Medpor scaffolds. Scale bar refers to 30 μm. b Human Dermal Fibroblast (HDF) adhesion after 24 h on PU 
and Medpor scaffolds. P values * < 0.05 ** < 0.01. c RT-qPCR analysis of adhesion related expression markers after 24 h on PU and Medpor scaffolds. 
Ar showed significantly greater expression of adhesion markers than Medpor and PU (PU vs Ar p < 0.05, Medpor vs Ar *p < 0.01). Fold changes 
represents difference compared to housekeeping gene GAPDH of HDFs cell growing on tissue culture plastic. d HDF DNA content over 14 days on 
PU and Medpor scaffolds. Ar showed greater DNA content at 1, 4, 7, 10 and 14 days compared to PU and Medpor. PU; Unmodified polyurethane
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14 days compared to HDF on PU and Medpor scaffolds. 
Staining of collagen type I confirmed the increased pro-
tein expression at 14  days by the HDF on Ar scaffolds 
(Fig. 4b). Total collagen secretion (Fig. 4c) and hydroxy-
proline secretion (Fig. 4d) by the HDFs was also elevated 
on the Ar scaffolds compared to Medpor and PU scaf-
folds (p < 0.05).
Assessment of immune response in vitro
At 24  h macrophage adhesion was the greatest on Ar 
scaffolds compared to Medpor and PU scaffolds (Fig. 5a). 
There was greater adhesion of macrophages on Med-
por surfaces compared to PU (p < 0.05) (Fig.  5a). From 
days 2–14  days the macrophage DNA content was sig-
nificantly greater on Ar scaffolds compared to PU and 
Medpor (p < 0.05) (Fig.  5b) F-actin was used to study 
macrophage morphology. The actin staining demon-
strated more elongated cells (red arrows) on the Medpor 
and Ar scaffolds than the PU scaffolds (Additional file 1: 
Figure S1). ELISA technique was used to study cytokines 
release by the macrophages on the different surfaces 
(Additional file  2: Figure S2). Macrophages on Med-
por scaffolds showed enhanced secretion of IL-1β, and 
TNF-α cytokines compared to PU and Ar scaffolds at 4, 7 
and 10 days. The macrophage secretion of IL-10 was the 
greatest on the Ar scaffolds at 7 and 10  days compared 
to PU and Medpor scaffolds (Additional file 2: Figure S2).
In vivo assessment of tissue integration and angiogenesis
Scaffolds of PU, Ar, and Medpor were implanted subcu-
taneously for 12  weeks to assess tissue integration and 
angiogenesis. H&E staining was used to compare levels 
of tissue integration between the scaffolds (Fig.  6a, b). 
At 6 weeks Ar and Medpor showed similar levels of tis-
sue integration, which was significantly higher than PU 
scaffolds (p < 0.05). The tissue ingrowth at 12  weeks of 
Ar scaffolds had doubled and significantly greater than 
the Medpor and PU scaffolds (p < 0.05). The PU and 
Medpor scaffolds showed similar tissue ingrowth at 
12 weeks (Fig. 6). Massons trichrome demonstrated that 
Ar showed the greatest levels of integration by 12 weeks 
(p < 0.05). Masson Trichrome also demonstrated simi-
lar levels of integration of PU and Medpor scaffolds at 
12  weeks (Fig.  6). To compare levels of angiogenesis 
CD31 staining was used to identify blood vessels within 
the newly formed tissue (Fig. 7). At 12 weeks, Ar showed 
greater CD31 staining than PU and Medpor (Fig.  7a, 
b). CD31 staining was also greater on the PU scaffolds 
than Medpor at 12  weeks (p < 0.05). CD68 stained the 
macrophages in the newly formed tissue to assess the 
immune response between the scaffolds. There were 
similar levels of CD68 positive cells on the three scaffolds 
after 12 weeks (Fig. 7c).
Discussion
In this study, a nanocomposite polyurethane (PU) was 
compared with argon modified polyurethane and clini-
cally available Medpor to determine its applicability 
to be used for facial cartilage reconstruction. The three 
material surfaces were compared for levels of tissue inte-
gration and angiogenesis. Argon polyurethane nanocom-
posite scaffolds supported cell attachment, proliferation 
and ECM formation in vitro as well as tissue integration 
and angiogenesis in vivo.
Protein adsorption is vital to determining cell adhesion 
onto biomaterials surfaces [33]. The Ar surfaces demon-
strated the highest protein adsorption when compared 
to Medpor surfaces. The greater protein adsorption on 
the Ar scaffolds could have provided a greater number of 
anchorage sites for cell attachment. Protein conformation 
Fig. 3 Assessment of angiogenesis on polyurethane (PU), argon (Ar) and Medpor scaffolds. a Vascular Endothelial Growth Factor (VEGF) secretions 
by the human dermal fibroblast (HDFs) on PU and Medpor after 4, 7, 10 and 14 days. b RT-qPCR of Vascular Endothelial Growth Factor (VEGF) on PU 
and Medpor scaffolds after 14 days. Fold changes represents difference compared to housekeeping gene GAPDH of HDFs cell growing on tissue 
culture plastic. P values * < 0.05 ** < 0.01. PU; Unmodified polyurethane
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studies using fibronectin and vitronectin were also con-
ducted to understand protein adsorption on the surfaces 
in more detail. The two proteins showed higher confor-
mation on Ar scaffolds than on PU and Medpor sur-
faces allowing for greater bioactivity of the protein and 
consequently greater cell adhesion. The upregulation of 
cell adhesion related genes including vinculin, talin, and 
paxillin by the HDFs on the Ar compared to Medpor 
scaffolds, highlights the greater cell adhesion on the Ar 
surfaces. Cell growth is influenced by cell adhesion to the 
biomaterial surface. The Ar scaffolds allowed for greater 
cell adhesion due to enhanced protein adsorption com-
pared to Medpor scaffolds, which led to greater growth 
over time in vitro.
The protein adsorption was varied on the scaffolds due 
to the differences in the surface properties of PU, Ar and 
Medpor scaffolds (Table 1). The three scaffolds had var-
ied tensile mechanical properties. For example Medpor 
had a Young’s Elastic Modulus of 140.09 ± 0.04 in tension, 
which is 35-fold times higher than Ar scaffolds. The sur-
face topography of the scaffolds was also different, with 
varying roughness values between the three surfaces. Ar 
scaffolds have a roughness of 12 ± 2  nm, whereas Med-
por has a roughness of 190 nm using AFM analysis. The 
surface wettability is also different for example the water 
contact angle of Ar scaffolds is on average 12° compared 
to Medpor at 105°. In summary, Ar scaffolds are less stiff, 
less rough and less hydrophobic than Medpor scaffolds. 
Protein adsorption onto a material surface is influenced 
Fig. 4 Assessment of Extracellular Matrix (ECM) formation by the human dermal fibroblasts (HDFs) after 14 days on polyurethane (PU), argon 
(Ar) and Medpor scaffolds. a RT-qPCR Analysis of ECM formation on all scaffolds. Ar showed a significantly greater expression of Collagen I (Col I), 
Collagen III (Col III), elastin, fibronectin (Fn) and laminin (Lm) after 14 days than Medpor and PU (*p < 0.05). Fold change represents difference to 
housekeeping gene GAPDH of HDFs growing on tissue culture plastic. b Collagen Type I expression by immunocytochemistry of the HDFs after 
14 days on all scaffolds. Green; Collagen Type I, Blue: Nuclei staining using DAPI. Scale bar refers to 50 μm. c Total collagen secretion by the HDFs on 
all scaffolds. d Hydroxyproline secretion by the HDFs on all scaffolds. P values * < 0.05 ** < 0.01 ***p < 0.001. PU; Unmodified polyurethane
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Fig. 5 Human macrophage in vitro studies on polyurethane (PU), argon (Ar) and Medpor scaffolds. a DNA quantification assay confirmed greater 
cell attachment to Ar scaffolds compared to Medpor and PU (Ar vs PU < 0.05, Ar vs Medpor *p < 0.05). b DNA quantification assay confirmed 
greater DNA content at 1, 4, 7 and 10 days on Ar scaffolds compared to Medpor and PU (Ar vs PU < 0.05, Ar vs Medpor p < 0.05). PU; Unmodified 
polyurethane
Fig. 6 Analysis of tissue integration and angiogenesis of polyurethane (PU), argon (Ar) and Medpor scaffolds following over subcutaneous 
implantation in a mouse model at 12 weeks. a H&E analysis and Masson Trichrome staining of tissue ingrowth of the PU, Ar and Medpor scaffolds. b 
Quantification of the tissue ingrowth over 12 weeks. Scale bar refers to 250 μm. P values * < 0.05. PU; Unmodified polyurethane
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by surface roughness and surface hydrophobicity and can 
determine protein quantity and conformation [34]. The 
differences in the scaffold’s topography but not mechani-
cal properties may have accounted for the varied tissue 
integration and vascularization response observed in this 
study.
Reports have demonstrated that protein adsorption is 
greater on hydrophobic surfaces [34–36]. However, there 
are also reports that have shown that protein adsorp-
tion can be varied on hydrophilic surfaces and protein 
adsorption can occur on hydrophilic surfaces [25]. Pro-
tein adsorption depends on the difference in the charge 
interaction and protein conformation of the scaffolds 
[25]. The function of a protein is determined by the 
protein conformation and the activity of the protein is 
controlled by the orientation and or its conformation 
[37]. The greater cell adhesion and growth observation 
observed on Ar scaffolds than Medpor could be due to 
both increased protein adsorption and more proteins 
were adsorbed in optimal conformations despite Ar scaf-
folds having a hydrophilic surface. With optimal proteins 
adsorption, more cells were able to adhere to the Ar scaf-
fold to form tissue and allow for vascularisation in vivo.
Surface roughness is also important in determining 
protein adsorption to a scaffold surface [36]. Medpor was 
shown to have a rougher surface than Ar. Studies have 
shown that increasing the roughness of a surface may 
increase the surface area for potential proteins adsorp-
tion [38]. However, the rougher surface may have also 
prevented the proteins to be adsorbed in an optimal 
conformation and created inactive reactive sites. The 
smoother surface of Ar compared to Medpor may have 
provided an optimal surface topography for protein 
adsorption in the correct configuration to induce the 
desired cell responses. The greater protein adsorption on 
Ar scaffolds would have allowed for greater cell adhesion, 
which would have contributed to greater tissue formation 
and vascularisation in  vivo. It is important to highlight 
Fig. 7 Angiogenesis and immune response analysis of the polyurethane (PU), argon (Ar) and Medpor scaffolds over 12 weeks in a subcutaneous 
implantation in a mouse model. a C31 staining after 12 weeks. b Quantification of vessel formation after 12 weeks. Scale bar refers to 250 μm. 
P values * < 0.05 ** < 0.01. c Macrophage infiltration over 12 weeks of the PU, Ar and Medpor scaffolds. CD68 staining was similar between the 
scaffolds within the pores. Scar bar refers to 50 μm. PU; Unmodified polyurethane
Table 1 Comparison of  polyurethane, argon modified polyurethane and  Medpor scaffolds characteristics 
including surface roughness, contact angle and mechanical properties
PU polyurethane
a Data is reproduced from Nayyer et al. Nanomedicine. 2014;10:235–46
Biomaterial characteristic (average) PU Medpor Argon modified PU
Surface roughness (Rq) 8 ± 1 119.0 ± 13.8a 11 ± 2
Contact angle (Degrees) 67 ± 7 45.67° ± 0.23a 12 ± 2
Tension Young’s elastic modulus (MPa) 4.2 ± 0.04 140.09 ± 0.04a 4.2 ± 0.8
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that protein adsorption is a complex process and does 
not only depend on vitronectin and fibronectin adsorp-
tion, which were the proteins evaluated in this study. 
After implantation in  vivo, several protein adsorb onto 
the implant surface including plasma proteins, albumin, 
fibrinogen and many more [39–41]. Hence, future stud-
ies must examine the behaviour of several other proteins 
in human plasma not only vitronectin and fibronectin to 
completely comprehend the protein-surface interaction 
that is occurring on the Ar scaffolds.
The subcutaneous implantation of the scaffolds allowed 
for assessment of tissue integration and angiogenesis over 
12 weeks. Tissue integration and angiogenesis are vital to 
allow for anchorage of the implant in  vivo [42]. The Ar 
scaffolds allowed for greater tissue formation at 12 weeks 
compared to Medpor. The upregulation of genes associ-
ated with the formation of extracellular matrix includ-
ing collagen type I, elastin and laminin by the HDFs on 
the Ar scaffolds may have allowed for a greater tissue 
ingrowth in  vivo. The Masson Trichrome staining also 
highlighted the greater collagen formation in vivo on the 
Ar scaffolds. The greater cell adhesion on the Ar scaffolds 
due to improved protein adsorption allowed for greater 
cell growth, which allowed for greater ECM production 
in vitro and in vivo.
Vascularisation of the scaffolds in vivo was determined 
by CD31 staining. At 6 weeks all scaffolds shown minimal 
vessel formation but by 12 weeks Ar scaffolds allowed for 
greater vessel ingrowth compared to Medpor. The VEGF 
growth factor is known to induce pathways responsible 
for vessel formation [43]. The HDFs on Ar scaffolds dem-
onstrated increased levels of VEGF secretion as well as 
mRNA expression of VEGF in vitro compared to Medpor, 
which may have allowed for greater vascularisation in vivo.
The immune response of the scaffolds was examined 
in  vitro and in  vivo. The greater macrophage adhesion 
onto the Ar scaffolds could be due to the greater pro-
tein adsorption observed on the scaffolds. The greater 
macrophage adhesion will have allowed for greater DNA 
content in culture over time. The release of the inflam-
matory cytokines mediators was important to examine 
on the different scaffolds to understand the inflammatory 
potential of the scaffolds. The pro-inflammatory media-
tors IL-1β and TNF-α, are known to be secreted by acti-
vated macrophage to regulate inflammation [44]. The 
IL-1β cytokine, is secreted by activated macrophages and 
governs inflammatory responses by modifying cell pro-
liferation, differentiation and apoptosis [45]. The IL-10 
cytokine, is considered an anti-inflammatory cytokine, 
secreted by activated macrophages and promotes heal-
ing and reduces inflammation [46]. In this study, mac-
rophages on Ar and PU scaffolds showed similar levels of 
cytokine mediators. On the other hand the macrophages 
on the Medpor showed greater levels of pro-inflamma-
tory mediators and lower levels of anti-inflammatory 
mediator IL-10 than PU and Ar.
All biomaterials undergo a foreign body response to 
the host tissue when implanted subcutaneously [47]. It is 
a structured sequence of events to allow for the host tis-
sue to accept the implant. To determine if the observed 
differences in the secretion of cytokines and behaviour 
of the macrophages caused any difference to the foreign 
body response the immune response to the scaffolds was 
examined in  vivo. The CD68 macrophages were exam-
ined in  vivo over 12  week on all three scaffolds. There 
was a similar decrease in the macrophage response over 
the 12  weeks. Typically all implants trigger the attach-
ment and recruitment of inflammatory cells as apart of 
the foreign body response reaction when a biomaterial is 
implanted [47]. Macrophages not only govern the inflam-
matory response by secreting chemokine, cytokines and 
growth factors but are also important in tissue regen-
eration [48]. Despite observing differences in the in vitro 
macrophage responses, no differences were observed 
in the in  vivo recruitment of macrophages to alter the 
immune response of the three scaffolds. Future work, will 
examine the proportion of activated and polarised mac-
rophages and their M1 or M2 phenotype to understand 
the significance of the in vitro findings and to understand 
their role in modification of inflammation and regenera-
tion. The M1 phenotype is involved in the killing of path-
ogens as a pro-inflammatory response [49–51] where as 
the M2 macrophages suppress the intracellular killing 
processes and reduction of pro-inflammatory responses 
by producing IL-10 [52]. The ELISA analysis may indicate 
there is greater amount of M2 macrophages on the Ar 
scaffolds due to the higher levels of IL-10 secretion.
Surface modification of scaffolds aims to provide 
appropriate responses to induce desired cell responses. 
This study has shown that PSM using argon gas pro-
vides surface topographical and chemical signals to allow 
for greater tissue formation and vascularisation without 
influencing the scaffold properties or cell biocompatibil-
ity. Argon improved tissue formation and angiogenesis 
by creating an optimal surface for protein adsorption and 
orientation to allow for desired cell adhesion and growth. 
PSM can be easily used to modify other biomaterials 
including natural and synthetic scaffolds without alter-
ing their structural properties. Argon modification over-
comes the limitations with current physical and chemical 
surface modification techniques including problems with 
protein half-life and stability in  vivo. This study pro-
vides a simple tool by which scaffolds can be modified to 
improve tissue integration and angiogenesis.
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Conclusions
This study has provided extensive data that Ar nanocom-
posites scaffolds allowed for cell adhesion, growth and 
in  vivo tissue ingrowth and vascularisation to a greater 
degree than clinically used Medpor. Argon modified pol-
yurethane scaffolds have demonstrated to be a promising 
biomaterial to replace missing or damaged auricular car-
tilage. This study provides evidence that nanocomposites 
polyurethanes are promising to replace cartilage and can 
be explored further as a biomaterial for cartilage tissue 
engineering applications.
Additional files
Additional file 1: Figure S1. Human macrophage morphology on polyu-
rethane (PU), argon (Ar) and Medpor scaffolds after 24 h. F-actin staining 
demonstrates more elongated cells (red arrow) on the Medpor and Ar 
scaffolds than the PU scaffold. Some macrophages showed evidence of 
pseudopodia (yellow arrow). Scale bar refers to 50 μm. PU; Unmodified 
Polyurethane.
Additional file 2: Figure S2. Cytokine profile secreted from the mac-
rophages after 10 days in vitro on polyurethane (PU), argon (Ar) and 
Medpor scaffolds. [A] Tumor necrosis factor-α (TNF-α) secretion was 
significantly greater on Medpor than PU and Ar scaffolds at 4, 7 and 
10 days (*p < 0.05). [B] Interleukin-1β (IL-β) secretion was significantly 
greater on Medpor than PU and Ar scaffolds at 2, 7 and 10 days (*p < 0.05). 
[C] Interleukin-10 (IL-10) secretion was significantly greater on Ar than 
PU and Medpor scaffolds at 4, 7 and 10 days (*p < 0.05). PU; Unmodified 
Polyurethane.
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